Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Variation at position 162 of peroxisome proliferator-activated receptor alpha does not influence the effect of fibrates on cholesterol or triacylglycerol concentrations in hyperlipidaemic subjects
Autore:
Puckey, LH; Knight, BL;
Indirizzi:
Hammersmith Hosp, Imperial Coll Sch Med, MRC, Ctr Clin Sci,Lipoprot Grp, London W12 0NN, England Hammersmith Hosp London England W12 0NN rot Grp, London W12 0NN, England
Titolo Testata:
PHARMACOGENETICS
fascicolo: 7, volume: 11, anno: 2001,
pagine: 619 - 624
SICI:
0960-314X(200110)11:7<619:VAP1OP>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
PPAR-ALPHA; FATTY-ACIDS; GENE; METABOLISM; LIPOPROTEIN; EXPRESSION; ISOFORM; MICE;
Keywords:
diabetes; polymorphism; lipoprotein; HDL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Knight, BL Hammersmith Hosp, Imperial Coll Sch Med, MRC, Ctr Clin Sci,Lipoprot Grp, DuCane Rd, London W12 0NN, England Hammersmith Hosp DuCane Rd London England W12 0NN 0NN, England
Citazione:
L.H. Puckey e B.L. Knight, "Variation at position 162 of peroxisome proliferator-activated receptor alpha does not influence the effect of fibrates on cholesterol or triacylglycerol concentrations in hyperlipidaemic subjects", PHARMACOGEN, 11(7), 2001, pp. 619-624

Abstract

The fibrate group of drugs are widely used to lower plasma lipid concentrations, especially in diabetic subjects. They exert their effects by activating peroxisome proliferator-activated receptor a (PPAR alpha), which regulates the transcription of a number of genes involved in hepatic lipid metabolism. The discovery of polymorphisms in the PPAR alpha gene raises the possibility that different variants could be associated with different responses to fibrate therapy. We have examined this in a random sample of 96 lipid clinic subjects who showed a wide range of response to fibrates. Of the known polymorphisms in PPAR alpha, the only difference detected in this samplewas the Leu/Val change at position 162. However, this change did not influence baseline plasma cholesterol or triacylglycerol concentrations, and wasnot associated with any difference in the effectiveness of fibrate treatment. Thus, there is no evidence that variation in the PPAR alpha gene at position 162 is responsible for the differential response to fibrates in non-diabetic hyperlipidaemic subjects. Pharmacogenetics 11:619-624 (C) 2001 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 21:26:40